Sterile Injectable Drugs

Global Market Trajectory & Analytics

MCP16822

EXECUTIVE ENGAGEMENTS

POOL

1842
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

331
Interactions with Platform & by Email

PARTICIPANTS

74
Unique # Participated

VALIDATIONS

16
Responses Validated*

COMPANIES

42
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

177

PAGES

249

EDITION

6

PRICE

USD 5450

CODE

MCP16822


COMPETITIVE METRICS

COMPANY

D S N T

% *

AstraZeneca PLC

Gilead Sciences, Inc.

GlaxoSmithKline PLC

LipoSeuticals

Lisapharma

Pfizer, Inc.

Science, Inc.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Sterile Injectable Drugs estimated at US$486.6 Billion in the year 2020, is projected to reach a revised size of US$929.3 Billion by 2027, growing at aCAGR of 9.7% over the period 2020-2027. Small Molecule, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$390.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Large Molecule segment is readjusted to a revised 9.9% CAGR for the next 7-year period.
The Sterile Injectable Drugs market in the U.S. is estimated at US$144.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$161 Billion by the year 2027 trailing a CAGR of 9.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.2% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

SELECT PLAYERS

AstraZeneca PLC; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Pfizer, Inc.; Science, Inc.

SEGMENTS

» Drug Class (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Other Drug Classes) » Indication (Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases, Other Indications) » Type (Small Molecule, Large Molecule)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Sterile Injectable Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Sterile Injectable Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Sterile Injectable Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Large Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cytokines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Peptide Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Peptide Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Peptide Hormones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Cardiology and Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Cardiology and Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cardiology and Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Autoimmune by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Autoimmune by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Autoimmune by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
China Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
China Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Sterile Injectable Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Sterile Injectable Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Sterile Injectable Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
France Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
France Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Sterile Injectable Drugs by Type - Small Molecule and Large Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Sterile Injectable Drugs by Type - Percentage Breakdown of Value Sales for Small Molecule and Large Molecule for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Sterile Injectable Drugs by Drug Class - Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Sterile Injectable Drugs by Drug Class - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines and Other Drug Classes for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Sterile Injectable Drugs by Indication - Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Sterile Injectable Drugs by Indication - Percentage Breakdown of Value Sales for Cardiology and Metabolic Disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Pain, Infectious Diseases and Other Indications for the Years 2012, 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com